Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adl-5859. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 19/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adl-5859 SCHEMBL29519892 | 0.99 | OPRD1 (0.98) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL471596 | 0.96 | OPRD1 (0.93) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL471640 | 0.94 | OPRD1 (0.89) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL467495 | 0.90 | OPRD1 (0.82) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL471683 | 0.89 | OPRD1 (0.81) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL471557 | 0.89 | OPRD1 (0.79) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL12029876 | 0.89 | OPRD1 (0.79) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL10258125 | 0.89 | OPRD1 (0.79) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL10258328 | 0.88 | OPRD1 (0.78) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 | |
| SCHEMBL10258789 | 0.88 | OPRD1 (0.78) | OPRD1KCNH2MRGPRX2CYP2D6OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| EP-1675847-B1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORP (US) | 2012-12-05 | — | — | EP | claimed |
| US-7638527-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-12-29 | — | — | US | claimed |
| EP-2063886-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | Adolor Corporation (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1675847-A4 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORP (US) | 2008-08-20 | — | — | EP | claimed |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CALIXA THERAPEUTICS, INC. | 2008-05-22 | — | — | US | claimed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | claimed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | claimed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| JP-2007507532-A | — | — | 2007-03-29 | — | — | JP | claimed |
| EP-1675847-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | claimed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | claimed |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12594333-B2 | Methods of treating inflammatory arthritis using IL-17 antagonists | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4116325-B1 | METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | NOVARTIS AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1675847-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | disclosed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, IL5 | OPRD1 2695/4885KCNH2 2719/4885MRGPRX2 1483/4885 |
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885KCNH2 4256/4885MRGPRX2 51/4885 |
| US-20080119452-A1 | METHODS FOR ENHANCING COGNITIVE FUNCTION | CHAT, GRIN2C, GRIN2A | OPRD1 981/4885KCNH2 1960/4885MRGPRX2 2493/4885 |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885MRGPRX2 678/4885 |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885MRGPRX2 678/4885 |
| US-12594333-B2 | Methods of treating inflammatory arthritis using IL-17 antagonists | IL17A, IL15, IL15RA | OPRD1 4614/4885KCNH2 4445/4885MRGPRX2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.